AlphAIAlphAI — Financial news for AI agents
investing.comAUG 251 min read$CRSP

Citizens reaffirms CRISPR Therapeutics stock rating on gene therapy data

Citizens reiterated a Market Outperform rating and $80 price target for CRISPR Therapeutics (CRSP), citing upcoming gene therapy data and potential 40% upside. The firm highlighted the company's focus on severe hypertriglyceridemia and refractory hypercholesterolemia, with a one-time therapy approach. CRISPR's label expansion for CASGEVY and Vertex Pharmaceuticals' promising data also support the positive outlook, according to Citizens.

Original reporting
investing.com
Published Aug 25, 2026, 9:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

Analyst coverage reiteration provides limited new insight; upcoming trial data will be the true catalyst.

02

Market read

The article offers a rating reaffirmation with modest upside potential, but no immediate trading trigger.

03

What to watch

Potential competition from other gene‑editing firms and regulatory timelines.

Relevance 4/10Novelty 2/10Timing: ahead of Aug 28 data presentation

Background

Citizens and H.C. Wainwright maintain $80 price targets for CRISPR Therapeutics amid ongoing clinical updates.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

Citizens reiterated a Market Outperform rating and $80 price target for CRISPR Therapeutics, citing upcoming CTX310 data presentation.

Expected impact

Potential slight upside if data is positive; otherwise limited effect.

Evidence & confidence

Rating repeat lacks new information; price move depends on upcoming trial results.

Market effects

Sector

Reinforces positive outlook for gene‑editing sector but limited broader impact.

Regional

US biotech market may see modest interest.

Global

Minimal global effect beyond niche investors.

Counterpoint

What could challenge this read

Rating repeat may be overly optimistic; upcoming data could disappoint.

Key entities

  • company
    CRISPR Therapeutics

    Biotech firm developing in‑vivo gene therapies.

  • analyst
    Citizens

    Equity research firm covering CRISPR Therapeutics.

Read at source← All news

Related articles

SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min
AUG 4
$CRSPMed

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.

zacks.com6 min